An observational study in Sepsis, sponsored by Emory University. Not yet recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Emory University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Sepsis by Emory University — 2 open to participants now, 2 under way, none of them phase 3. Sepsis · Emory University.
Among the 10 studies in Sepsis by Emory University, this one is the only one that started in 2027, is one of 5 observational ones, and was the 9th registered.
2,421 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →2 of the 10 studies in Sepsis by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,200 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 501 across the 5 interventional studies, 1,200 across the 5 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
1 of the studies in Sepsis by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05943938Emory UniversityComparison of Sepsis Prediction Algorithms | 2027-09-01 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Sepsis by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis is a severe response to infection resulting in organ dysfunction and often leading to death. More than 1.5 million people get sepsis every year in the U.S., and 270,000 Americans die from sepsis annually. Delays in the diagnosis of sepsis lead to increased mortality. Several clinical decision support algorithms exist for the early identification of sepsis. The research team will compare the performance of three sepsis prediction algorithms to identify the algorithm that is most accurate and clinically actionable. The algorithms will run in the background of the electronic health record (EHR) and the predictions will not be revealed to patients or clinical staff. In this current evaluation study, the algorithms will not affect any part of a patient's care. The algorithms will be deployed across the Emory healthcare system on data from all patients presenting to the emergency department.
The primary goal of this study is to prospectively evaluate three sepsis prediction algorithms that are embedded in the EHR. The models will be deployed in a "shadow" mode, and the results will not be displayed to the treatment team during this study. Two of the algorithms are proprietary algorithms of the EHR provider (Epic). The third algorithm is an internally developed, open-source algorithm.
The algorithms will compute the probability of sepsis at periodic intervals and will continue to run on a patient's data until the patient's discharge, death, or upon initiation of intravenous antibiotics (at which point there is an indirect record of clinical suspicion of an infection).
All adult patients admitted through the ED from the time they arrive at the hospital until discharge, death, or initiation of intravenous antibiotics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All adult patients presenting to Emergency Departments (ED) in the Emory Healthcare system
Other: Epic Sepsis Model Version - 1 · Other: Epic Sepsis Model Version - 2 · Other: Emory Sepsis Model
The Epic Sepsis Model (ESM) version 1, a proprietary sepsis prediction model.
Also known as: Proprietary Epic sepsis algorithm -1
The Epic Sepsis Model (ESM) version 2, a proprietary sepsis prediction model.
Also known as: Proprietary Epic sepsis algorithm -2
Emory internal algorithm
Also known as: Emory Sepsis Algorithm
Patient hospitalization-level area under curve (AUC) for identification of sepsis,
Definition of Sepsis using the Centers for Disease Control and Prevention (CDC) Adult Sepsis Surveillance.
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Sensitivity, specificity, and Positive and Negative Predictive Value of algorithms
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Lead time to antibiotic administration
The time between the initial deployment of the alert in patients confirmed to have sepsis (ture positives) and the physician's ordering of intravenous antibiotic therapy.
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Percent expected increase in unnecessary antibiotics
Percent of patients who were incorrectly identified as having sepsis (false positives), and received antibiotics.
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Number needed to screen
The number of alerts that would need to be processed to find one true positive sepsis.
Time frame: Duration of hospital stay (or death), an expected average of 30 days
Number of Total and false alert burden
The number of Total and false alert burden cumulative across all study patients over the study period
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Time-horizon based AUCs
AUCs will be calculated at 3 pre-specified time horizons.
Time frame: 4 hours, 8 hours, and 24 hours
Accuracy and calibration by subgroup
The AUC and calibration curves will be compared by sex and race to ensure predictive accuracy is equal across subgroups.
Time frame: Duration of hospital stay (until discharge or death), an expected average of 30 days
Plan to share: Yes — The investigators will share individual participant data that underlie the results reported in an article, after deidentification (text, tables, figures, and appendices).
Supporting information: Study protocol
Time frame: Data will be shared beginning 6 months after publication, without a specified end date.
Access criteria: To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Sep 2027, 6 months later.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 6 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Jun 2026 → Mar 2027, primary completion Dec 2026 → Sep 2027 and completion Dec 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.